Printer Friendly

AbbVie Phase 2b Data Show Upadacitinib Reduces Pruritis in Atopic Dermatitis as Early as Week One.

M2 PHARMA-February 20, 2018-AbbVie Phase 2b Data Show Upadacitinib Reduces Pruritis in Atopic Dermatitis as Early as Week One

(C)2018 M2 COMMUNICATIONS

- North Chicago, Illinois-based global biopharmaceutical company AbbVie (NYSE: ABBV) has presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis at the 2018 American Academy of Dermatology annual meeting, the company said.

Across all doses (30/15/7.5 mg once-daily), additional exploratory results showed significant reduction of select symptoms of atopic dermatitis in upadacitinib patients, including reduction in itch (pruritus) at week 1 and improvement in the extent and severity of skin lesions at week 2.

The most common adverse events were upper respiratory tract infection, atopic dermatitis worsening, and acne.

This dose-ranging study is an ongoing 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study designed to evaluate the safety and efficacy of upadacitinib in adult patients with moderate to severe atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable.

Upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an important role in the pathophysiology of immune-mediated disorders. Phase 3 trials of upadacitinib in rheumatoid arthritis, psoriatic arthritis, and Crohn's disease are ongoing.

It is also being evaluated as a potential treatment for ankylosing spondylitis, and the company plans to begin registration-enabling studies in atopic dermatitis, ulcerative colitis, and giant cell arteritis this year.

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for complex and critical conditions. The company's mission is to improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 20, 2018
Words:294
Previous Article:Avillion Opens IND for Phase 2 Study of Anti-IL-17 A/F Nanobody for treatment of Psoriasis.
Next Article:AbbVie Presents Positive Results from Phase 3 Trials of Risankizumab for Treatment of Psoriasis at 2018 Dermatology Meeting.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters